SCHEMBL5135923

SCHEMBL5135923

CCCCN(Cc1ccccc1Br)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
TSHR P16473 5/20 0.42
HDAC1 Q13547 1/20 0.40
HSD17B10 Q99714 5/20 0.39
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 4/20 0.39
HPGD P15428 4/20 0.39
CYP3A4 P08684 3/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
NFKB1 P19838 1/20 0.38
CYP2C19 P33261 1/20 0.38
LMNA P02545 1/20 0.37
BLM P54132 1/20 0.37
NR1H3 Q13133 1/20 0.36
DRD2 P14416 1/20 0.36
DRD3 P35462 1/20 0.36
PDE4B Q07343 1/20 0.35
ATP4A P20648 1/20 0.35
ATP4B P51164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5074378 0.97 C5AR1 (0.41) C5AR1TSHRHDAC1HSD17B10ALDH1A1
SCHEMBL5135547 0.96 C5AR1 (0.43) C5AR1TSHRHDAC1HSD17B10ALDH1A1
SCHEMBL5170283 0.96 TSHR (0.40) C5AR1TSHRHDAC1HSD17B10ALDH1A1
SCHEMBL5135042 0.93 C5AR1 (0.44) C5AR1TSHRHDAC1HSD17B10ALDH1A1
SCHEMBL5135025 0.91 C5AR1 (0.45) C5AR1TSHRHSD17B10ALDH1A1KDM4E
SCHEMBL5137095 0.89 C5AR1 (0.45) C5AR1TSHRHDAC1HSD17B10ALDH1A1
SCHEMBL650694 0.88 TSHR (0.51) C5AR1TSHRHDAC1HSD17B10ALDH1A1
SCHEMBL5137577 0.88 C5AR1 (0.43) C5AR1TSHRHDAC1HSD17B10ALDH1A1
SCHEMBL5136516 0.88 C5AR1 (0.43) C5AR1TSHRHDAC1HSD17B10ALDH1A1
SCHEMBL5134961 0.88 C5AR1 (0.43) C5AR1TSHRHDAC1HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed